American Healthcare REIT Inc

AHR remains in a Stage 2 advancing uptrend confirmed by a strong Momentum Breakout, but price is extended above rising EMAs with visible exhaustion and extreme overbought readings. The medium-term bias stays bullish, so we recommend deferring buys (Stalk) until pullbacks into the rising 9 and 21 EMA support zone are favorably accepted rather than buying into the current extension.

• ↑Normalized FFO up 31.6% YoY to $0.50/share in Q1 2026
• ↑Same-store NOI grew 12.1% for ninth straight quarter of double-digit gains
• ↓Negative earnings yield and weak book-to-price suggest overvaluation